DOI: 10.1200/jco.2000.18.22.3837. Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia

Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia

10.1200/jco.2000.18.22.3837

Crossref journal-article

American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology (233)

Abstract

PURPOSE: Little is known about nonrandom deletions of chromosome bands 13q12 to 13q14 (13q12–14) in acute lymphoblastic leukemia (ALL). We determined the prognostic significance of cytogenetically identified breakpoints in 13q12–14 in children with newly diagnosed ALL treated on Children’s Cancer Group protocols from 1988 to 1995. PATIENTS AND METHODS: Breakpoints in 13q12–14 were identified in 36 (2%) of the 1,946 cases with accepted cytogenetic data. Outcome analysis used standard life-table methods. RESULTS: Seventeen patients (47%) with an abnormal 13q12–14 were classified, according to the National Cancer Institute (NCI), as poor risk, and 15 patients (42%) were standard risk; four (11%) were infants less than 12 months of age. Eight cases had balanced rearrangements of 13q12–14, 27 patients had a partial loss of 13q, and one had both a partial gain and a partial loss. The most frequent additional abnormalities among these patients were an abnormal 12p, a del(6q), a del(9p), a 14q11 breakpoint, and an 11q23 breakpoint. Nineteen patients were pseudodiploid, 10 were hyperdiploid, and seven were hypodiploid. Patients with an abnormal 13q12–14 had significantly worse event-free survival than patients lacking such an abnormality, with estimates at 6 years of 61% (SD = 14%) and 74% (SD = 1%), respectively (P = .04; relative risk = 1.74). Overall survival, however, was similar for the two groups (P = .25). The prognostic effect of an abnormal 13q was attenuated in a multivariate analysis adjusted for NCI risk status and ploidy (P = .72). CONCLUSION: Aberrations of 13q12–14 may contribute to leukemogenesis of childhood ALL and confer increased risk of treatment failure but are associated with other poor-risk features.

Bibliography

Heerema, N. A., Sather, H. N., Sensel, M. G., Lee, M. K., Hutchinson, R. J., Nachman, J. B., Reaman, G. H., Lange, B. J., Steinherz, P. G., Bostrom, B. C., Gaynon, P. S., & Uckun, F. M. (2000). Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 18(22), 3837â3844.

Authors 12

Nyla A. Heerema (first)
Harland N. Sather (additional)
Martha G. Sensel (additional)
Mei K. Lee (additional)
Raymond J. Hutchinson (additional)
James B. Nachman (additional)
Gregory H. Reaman (additional)
Beverly J. Lange (additional)
Peter G. Steinherz (additional)
Bruce C. Bostrom (additional)
Paul S. Gaynon (additional)
Fatih M. Uckun (additional)

References 28 Referenced 26

10.1182/blood.V89.2.734
10.1038/sj.onc.1201764
10.1002/gcc.2870120408
Garcia-Marco JA, Navarro B, Caldas C: Confirmation of frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukaemia. Br J Haematol 99: 708,1997-709, (letter) (10.1182/blood.V88.5.1568.1568)
10.1002/(SICI)1098-2264(199803)21:3<223::AID-GCC6>3.0.CO;2-1
Hawthorn LA, Chapman R, Oscier D, et al: The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 8: 1415,1993-1419,
10.1038/ng0193-67
Chapman RM, Corcoran MM, Gardiner A, et al: Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukemogenesis in chronic B-cell lymphocytic leukaemia. Oncogene 9: 1289,1994-1293,
10.1073/pnas.95.10.5712
10.1093/hmg/7.4.637
10.1182/blood.V92.5.1735
MacDonald D, Aguiar RC, Mason PJ, et al: A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: A review. Leukemia 9: 1628,1995-1630, (10.1182/blood.V86.2.834.bloodjournal862834)
10.1182/blood.V93.3.1025
Coignet LJA, Lima CSP, Min T, et al: Myeloid and lymphoid-specific breakpoint cluster regions in chromosome 13q14 in acute leukemia. Blood 92: 71a,1998 (abstr 288) (10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C)
10.1182/blood.V73.4.1000.1000
Uckun FM, Sather HN, Gaynon P, et al: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: A report from the Children’s Cancer Group. Blood 90: 28,1997-35,
Hutchinson R, Bertolone S, Cooper H, et al: Early marrow response predicts outcome for patients with low risk ALL: Results of CCG-1881. Proc Am Soc Clin Oncol 13: 319,1994 (abstr 1051)
Lange B, Sather H, Weetman R, et al: Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): A Children’s Cancer Group study, CCG-1891. Blood 90: 559a,1997 (abstr 2489)
10.1200/JCO.1996.14.1.18
10.1056/NEJM199806043382304
10.1200/JCO.1998.16.3.920
10.1002/1097-0142(19910815)68:4<751::AID-CNCR2820680416>3.0.CO;2-T
10.1200/JCO.1999.17.2.445
10.1182/blood.V83.8.2274.2274
10.1080/01621459.1958.10501452
10.1038/bjc.1977.1
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163,1966-170,
Heerema NA, Nachman JB, Sather HN, et al: Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children’s Cancer Group. Blood 94: 4036,1999-4045,

Dates

Type	When
Created	8 years, 6 months ago (Feb. 24, 2017, 2:10 a.m.)
Deposited	3 years, 3 months ago (May 25, 2022, 5:38 p.m.)
Indexed	1 year, 9 months ago (Nov. 14, 2023, 10:03 a.m.)
Issued	24 years, 9 months ago (Nov. 15, 2000)
Published	24 years, 9 months ago (Nov. 15, 2000)
Published Print	24 years, 9 months ago (Nov. 15, 2000)

Funders 0

None

BibTeX

@article{Heerema_2000, title={Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia}, volume={18}, ISSN={1527-7755}, url={http://dx.doi.org/10.1200/jco.2000.18.22.3837}, DOI={10.1200/jco.2000.18.22.3837}, number={22}, journal={Journal of Clinical Oncology}, publisher={American Society of Clinical Oncology (ASCO)}, author={Heerema, Nyla A. and Sather, Harland N. and Sensel, Martha G. and Lee, Mei K. and Hutchinson, Raymond J. and Nachman, James B. and Reaman, Gregory H. and Lange, Beverly J. and Steinherz, Peter G. and Bostrom, Bruce C. and Gaynon, Paul S. and Uckun, Fatih M.}, year={2000}, month=nov, pages={3837–3844} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2023,
        11,
        14
      ]
    ],
    "date-time": "2023-11-14T15:03:31Z",
    "timestamp": 1699974211179
  },
  "reference-count": 28,
  "publisher": "American Society of Clinical Oncology (ASCO)",
  "issue": "22",
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2000,
        11,
        15
      ]
    ]
  },
  "abstract": "<jats:p> PURPOSE: Little is known about nonrandom deletions of chromosome bands 13q12 to 13q14 (13q12\u201314) in acute lymphoblastic leukemia (ALL). We determined the prognostic significance of cytogenetically identified breakpoints in 13q12\u201314 in children with newly diagnosed ALL treated on Children\u2019s Cancer Group protocols from 1988 to 1995. </jats:p><jats:p> PATIENTS AND METHODS: Breakpoints in 13q12\u201314 were identified in 36 (2%) of the 1,946 cases with accepted cytogenetic data. Outcome analysis used standard life-table methods. </jats:p><jats:p> RESULTS: Seventeen patients (47%) with an abnormal 13q12\u201314 were classified, according to the National Cancer Institute (NCI), as poor risk, and 15 patients (42%) were standard risk; four (11%) were infants less than 12 months of age. Eight cases had balanced rearrangements of 13q12\u201314, 27 patients had a partial loss of 13q, and one had both a partial gain and a partial loss. The most frequent additional abnormalities among these patients were an abnormal 12p, a del(6q), a del(9p), a 14q11 breakpoint, and an 11q23 breakpoint. Nineteen patients were pseudodiploid, 10 were hyperdiploid, and seven were hypodiploid. Patients with an abnormal 13q12\u201314 had significantly worse event-free survival than patients lacking such an abnormality, with estimates at 6 years of 61% (SD = 14%) and 74% (SD = 1%), respectively (P = .04; relative risk = 1.74). Overall survival, however, was similar for the two groups (P = .25). The prognostic effect of an abnormal 13q was attenuated in a multivariate analysis adjusted for NCI risk status and ploidy (P = .72). </jats:p><jats:p> CONCLUSION: Aberrations of 13q12\u201314 may contribute to leukemogenesis of childhood ALL and confer increased risk of treatment failure but are associated with other poor-risk features. </jats:p>",
  "DOI": "10.1200/jco.2000.18.22.3837",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2017,
        2,
        24
      ]
    ],
    "date-time": "2017-02-24T07:10:13Z",
    "timestamp": 1487920213000
  },
  "page": "3837-3844",
  "source": "Crossref",
  "is-referenced-by-count": 26,
  "title": "Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia",
  "prefix": "10.1200",
  "volume": "18",
  "author": [
    {
      "given": "Nyla A.",
      "family": "Heerema",
      "sequence": "first",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Harland N.",
      "family": "Sather",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Martha G.",
      "family": "Sensel",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Mei K.",
      "family": "Lee",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Raymond J.",
      "family": "Hutchinson",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "James B.",
      "family": "Nachman",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Gregory H.",
      "family": "Reaman",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Beverly J.",
      "family": "Lange",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Peter G.",
      "family": "Steinherz",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Bruce C.",
      "family": "Bostrom",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Paul S.",
      "family": "Gaynon",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    },
    {
      "given": "Fatih M.",
      "family": "Uckun",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "From the Department of Genetics, Parker Hughes Institute; Children\u2019s Cancer Group ALL Biology Reference Laboratory and Parker Hughes Institute, St Paul; Division of Hematology-Oncology, Children\u2019s Hospitals and Clinics, Minneapolis, MN; Group Operations Center, Children\u2019s Cancer Group, Arcadia; Department of Preventive Medicine, University of Southern California; Department of Pediatric Hematology-Oncology, Children\u2019s Hospital, Los Angeles, CA; Department of Pediatrics, Hematology-Oncology, University of..."
        }
      ]
    }
  ],
  "member": "233",
  "reference": [
    {
      "key": "R1-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1182/blood.V89.2.734"
    },
    {
      "key": "R2-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/sj.onc.1201764"
    },
    {
      "key": "R3-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/gcc.2870120408"
    },
    {
      "key": "R4-0524",
      "doi-asserted-by": "crossref",
      "unstructured": "Garcia-Marco  JA,   Navarro  B,   Caldas  C:   Confirmation of frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukaemia.   Br J Haematol 99:  708,1997-709,    (letter)",
      "DOI": "10.1182/blood.V88.5.1568.1568"
    },
    {
      "key": "R5-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/(SICI)1098-2264(199803)21:3<223::AID-GCC6>3.0.CO;2-1"
    },
    {
      "key": "R6-0524",
      "unstructured": "Hawthorn  LA,   Chapman  R,   Oscier  D,  et al:  The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene.   Oncogene 8:  1415,1993-1419,"
    },
    {
      "key": "R7-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/ng0193-67"
    },
    {
      "key": "R8-0524",
      "unstructured": "Chapman  RM,   Corcoran  MM,   Gardiner  A,  et al:  Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukemogenesis in chronic B-cell lymphocytic leukaemia.   Oncogene 9:  1289,1994-1293,"
    },
    {
      "key": "R9-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1073/pnas.95.10.5712"
    },
    {
      "key": "R10-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/hmg/7.4.637"
    },
    {
      "key": "R11-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1182/blood.V92.5.1735"
    },
    {
      "key": "R12-0524",
      "doi-asserted-by": "crossref",
      "unstructured": "MacDonald  D,   Aguiar  RC,   Mason  PJ,  et al:  A new myeloproliferative disorder associated with chromosomal translocations involving 8p11:   A review.   Leukemia 9:  1628,1995-1630,",
      "DOI": "10.1182/blood.V86.2.834.bloodjournal862834"
    },
    {
      "key": "R13-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1182/blood.V93.3.1025"
    },
    {
      "key": "R14-0524",
      "doi-asserted-by": "crossref",
      "unstructured": "Coignet  LJA,   Lima  CSP,   Min  T,  et al:  Myeloid and lymphoid-specific breakpoint cluster regions in chromosome 13q14 in acute leukemia.   Blood 92:  71a,1998  (abstr 288)",
      "DOI": "10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C"
    },
    {
      "key": "R16-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1182/blood.V73.4.1000.1000"
    },
    {
      "key": "R17-0524",
      "unstructured": "Uckun  FM,   Sather  HN,   Gaynon  P,  et al:  Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia:   A report from the Children\u2019s Cancer Group.   Blood 90:  28,1997-35,"
    },
    {
      "key": "R18-0524",
      "unstructured": "Hutchinson  R,   Bertolone  S,   Cooper  H,  et al:  Early marrow response predicts outcome for patients with low risk ALL:   Results of CCG-1881.   Proc Am Soc Clin Oncol 13:  319,1994  (abstr 1051)"
    },
    {
      "key": "R19-0524",
      "unstructured": "Lange  B,   Sather  H,   Weetman  R,  et al:  Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL):   A Children\u2019s Cancer Group study, CCG-1891.   Blood 90:  559a,1997  (abstr 2489)"
    },
    {
      "key": "R20-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.1996.14.1.18"
    },
    {
      "key": "R21-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1056/NEJM199806043382304"
    },
    {
      "key": "R22-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.1998.16.3.920"
    },
    {
      "key": "R23-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/1097-0142(19910815)68:4<751::AID-CNCR2820680416>3.0.CO;2-T"
    },
    {
      "key": "R24-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.1999.17.2.445"
    },
    {
      "key": "R25-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1182/blood.V83.8.2274.2274"
    },
    {
      "key": "R27-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1080/01621459.1958.10501452"
    },
    {
      "key": "R28-0524",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/bjc.1977.1"
    },
    {
      "key": "R29-0524",
      "unstructured": "Mantel  N:   Evaluation of survival data and two new rank order statistics arising in its consideration.   Cancer Chemother Rep 50:  163,1966-170,"
    },
    {
      "key": "R30-0524",
      "unstructured": "Heerema  NA,   Nachman  JB,   Sather  HN,  et al:  Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia:   A report from the Children\u2019s Cancer Group.   Blood 94:  4036,1999-4045,"
    }
  ],
  "container-title": "Journal of Clinical Oncology",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2000.18.22.3837",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        5,
        25
      ]
    ],
    "date-time": "2022-05-25T21:38:12Z",
    "timestamp": 1653514692000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://ascopubs.org/doi/10.1200/JCO.2000.18.22.3837"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2000,
        11,
        15
      ]
    ]
  },
  "references-count": 28,
  "journal-issue": {
    "issue": "22",
    "published-print": {
      "date-parts": [
        [
          2000,
          11,
          15
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1200/JCO.2000.18.22.3837"
  ],
  "URL": "http://dx.doi.org/10.1200/JCO.2000.18.22.3837",
  "relation": {},
  "ISSN": [
    "0732-183X",
    "1527-7755"
  ],
  "subject": [],
  "container-title-short": "JCO",
  "published": {
    "date-parts": [
      [
        2000,
        11,
        15
      ]
    ]
  }
}